BTIG Research Cuts Organogenesis (NASDAQ:ORGO) Price Target to $8.00

Organogenesis (NASDAQ:ORGO) had its target price cut by BTIG Research from $9.00 to $8.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently issued reports on ORGO. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.67.

Organogenesis Price Performance

ORGO opened at $3.21 on Friday. Organogenesis has a fifty-two week low of $2.61 and a fifty-two week high of $7.08. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.32 and a current ratio of 3.62. The firm has a 50-day moving average of $4.23 and a 200 day moving average of $4.58. The firm has a market cap of $412.93 million, a P/E ratio of 40.13 and a beta of 1.43.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Thursday, February 26th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.10. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. The firm had revenue of $225.61 million during the quarter, compared to the consensus estimate of $172.68 million. On average, research analysts expect that Organogenesis will post -0.07 EPS for the current year.

Insider Activity at Organogenesis

In related news, Director Glenn H. Nussdorf sold 200,000 shares of Organogenesis stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the sale, the director directly owned 2,565,591 shares in the company, valued at $13,187,137.74. This trade represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 33.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Organogenesis

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP purchased a new stake in shares of Organogenesis during the third quarter valued at $25,000. State of Alaska Department of Revenue acquired a new stake in Organogenesis during the 3rd quarter worth about $25,000. Flagship Harbor Advisors LLC purchased a new stake in Organogenesis during the 4th quarter valued at about $34,000. Federated Hermes Inc. grew its stake in Organogenesis by 52.8% during the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after purchasing an additional 2,953 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Organogenesis in the fourth quarter valued at about $57,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis News Roundup

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.